Floatz logo

19 assets in Primary Biliary Cholangitis

Therapeutic assets addressing Primary Biliary Cholangitis, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Ursodeoxycholic Acid
Primary Biliary Cholangitis
Xijing Hospital of Digestive DiseasesP4A (82)
Fenofibrate
Primary Biliary Cholangitis
Xijing Hospital of Digestive DiseasesP3BB (71)
Saroglitazar
Primary Biliary Cholangitis
Zydus Therapeutics Inc.P3BB (71)
cs0159
Primary Biliary Cholangitis
Cascade Pharmaceuticals, IncP3BB (68)
Obeticholic Acid
Primary Biliary Cholangitis
Intercept PharmaceuticalsP3BB (68)
Seladelpar
Primary Biliary Cholangitis
Gilead SciencesP3BB (68)
2-(P-(2-(P-CHLOROBENZAMIDO)ETHYL)PHENOXY)-2-METHYLPROPIONIC ACID
Primary Biliary Cholangitis
Intercept PharmaceuticalsP3BB (67)
Babaodan
Primary Biliary Cholangitis
Mei HanP4BB (65)
Setanaxib
Primary Biliary Cholangitis
Calliditas Therapeutics Suisse SAP2B (62)
Elafibranor
Primary Biliary Cholangitis
IpsenP3B (61)
K-808
Primary Biliary Cholangitis
Kowa Research Institute, Inc.P2B (60)
asc42
Primary Biliary Cholangitis
Gannex Pharma Co., Ltd.P2B (57)
Prednisone
Primary Biliary Cholangitis
Han YingP2/3B (57)
Nalmefene
Primary Biliary Cholangitis
Tharimmune IncP2CCC (53)
Volixibat
Primary Biliary Cholangitis
Mirum Pharmaceuticals, Inc.P2CCC (53)
Cnp-104
Primary Biliary Cholangitis
COUR Pharmaceutical Development Company, Inc.P1/2CCC (50)
Golexanolone
Primary Biliary Cholangitis
Umecrine Cognition ABP1/2CC (47)
pvt201
Primary Biliary Cholangitis
Parvus Therapeutics, Inc.P1CC (46)
her2bbζ/cd19t+ t cells
Primary Biliary Cholangitis
PersonGen BioTherapeutics (Suzhou) Co., Ltd.Early P1C (39)